Analysts on Wall Street project that Cardinal Health (CAH) will announce quarterly earnings of $2.92 per share in its forthcoming report, representing an increase of 14.5% year over year. Revenues are projected to reach $66.96 billion, increasing 4.6% from the same quarter last year.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Given this perspective, it's time to examine the average forecasts of specific Cardinal metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts forecast 'Revenue- Pharmaceutical and Specialty Solutions' to reach $61.90 billion. The estimate suggests a change of +4.6% year over year.
Analysts' assessment points toward 'Revenue- Other' reaching $1.78 billion. The estimate indicates a change of +8.3% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenue- Global Medical Products and Distribution' should come in at $3.28 billion. The estimate indicates a change of +3% from the prior-year quarter.
The average prediction of analysts places 'Segment profit- Pharmaceutical and Specialty Solutions' at $740.48 million. The estimate compares to the year-ago value of $667.00 million.
The consensus estimate for 'Segment profit- Other' stands at $191.65 million. Compared to the present estimate, the company reported $166.00 million in the same quarter last year.
The combined assessment of analysts suggests that 'Segment profit- Global Medical Products and Distribution' will likely reach $22.89 million. Compared to the present estimate, the company reported $46.00 million in the same quarter last year.
View all Key Company Metrics for Cardinal here>>>Cardinal shares have witnessed a change of +9.7% in the past month, in contrast to the Zacks S&P 500 composite's -0.9% move. With a Zacks Rank #3 (Hold), CAH is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power .
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Cardinal Health, Inc. (CAH): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).